PRMT5和CDKN2B在宫颈癌组织的表达及临床意义  

The expression and clinical significance of PRMT5 and CDKN2B in cervical cancer tissue

作　　者：胡晓菡[1] 周强[2] 孙武 陈静[4] 沈瀚[1] 李强[4] Hu Xiaohan;Zhou Qiang;Sun Wu;Chen Jing;Shen Han;Li Qiang(Department of Laboratory,Nanjing University School of Medicine Affiliated Gulou Hospital,Jiangsu Province,Nanjing 210008,China;不详)

机构地区：[1]南京大学医学院附属鼓楼医院检验科,210008 [2]南京大学医学院附属鼓楼医院病理科,210008 [3]南京大学医学院附属鼓楼医院肿瘤科,210008 [4]南京大学医学院附属鼓楼医院妇产科,210008

出　　处：《疑难病杂志》2024年第4期412-417,共6页Chinese Journal of Difficult and Complicated Cases

基　　金：江苏省医学科研项目(S2020066)。

摘　　要：目的研究蛋白精氨酸甲基转移酶5(PRMT5)、细胞周期蛋白依赖性激酶抑制剂2B(CDKN2B)在宫颈癌中的表达及临床意义。方法收集2019年3月—2020年3月南京大学医学院附属鼓楼医院妇产科诊治宫颈癌患者88例。免疫组织化学法检测宫颈癌和癌旁组织中PRMT5、CDKN2B表达;采用Spearman相关分析PRMT5与CDKN2B表达的相关性;比较不同临床特征宫颈癌癌组织中PRMT5、CDKN2B表达的差异;Kaplan-Meier曲线评估PRMT5、CDKN2B表达对宫颈癌患者无进展生存预后的影响;多因素Cox回归分析宫颈癌患者无进展生存预后的影响因素。结果癌组织中PRMT5蛋白阳性率70.45%(62/88),高于癌旁组织6.82%(6/88)(χ^(2)=75.155,P<0.001)。宫颈癌组织中CDKN2B阳性率22.73%(20/88),低于癌旁组织79.55%(71/88)(χ^(2)=75.336,P<0.001)。宫颈癌中PRMT5与CDKN2B呈负相关(r=-0.734,P<0.001)。FIGOⅠB2~ⅡA期、有淋巴结转移宫颈癌组织中PRMT5阳性率高于FIGOⅠA~ⅠB1期、无淋巴结转移者,而CDKN2B阳性率则降低(χ^(2)/P=6.359/0.012、4.606/0.032、5.205/0.023、3.893/0.048)。PRMT5阳性组3年累积无进展生存率74.19%(46/62),低于PRMT5阴性组92.31%(24/26)(Log-Rankχ^(2)=4.386,P=0.017)。CDKN2B阴性组3年累积无进展生存率75.00%(51/68),低于CDKN2B阳性组95.00%(19/20)(Log-Rankχ^(2)=4.423,P=0.012)。FIGO分期ⅠB2~ⅡA期、合并淋巴结转移、PRMT5阳性、CDKN2B阴性是影响宫颈癌患者无进展生存预后的独立危险因素[OR(95%CI)=1.407(1.159~1.696),1.464(1.201~1.784),1.614(1.189~2.192),1.595(1.191~2.136)]。结论宫颈癌组织中PRMT5表达升高,CDKN2B表达降低,两者与宫颈癌患者的不良临床病理特征有关,是评估宫颈癌预后的标志物。Objective To investigate the expression and clinical significance of protein arginine methyltransferase 5(PRMT5)and cyclin dependent kinase inhibitor 2B(CDKN2B)in cervical cancer.Methods The clinical data of 88 cervical cancer patients who treated in the Department of Obstetrics and Gynecology,Gulou Hospital Affiliated to Nanjing University School of Medicine from March 2019 to March 2020 were collected.Immunohistochemical method was used to detect the expression of PRMT5 and CDKN2B in cervical cancer and adjacent tissues.The correlation between PRMT5 and CDKN2B expression was analyzed using Spearman correlation analysis.The differences of PRMT5,CDKN2B in cervical cancer tissues with different clinical characteristics were compared.Kaplan-Meier curve was used to evaluate the impact of PRMT5 and CDKN2B expression on the progression free survival prognosis of cervical cancer patients.Multivariate Cox regression analysis was used to analyze factors influencing the progression free survival prognosis of cervical cancer patients.Results The positive rate of PRMT5 protein in cancer tissue was 70.45%(62/88),which was higher than 6.82%(6/88)in adjacent tissues(χ^(2)=75.155,P=<0.001).The positive rate of CDKN2B in cervical cancer tissue was 22.73%(20/88),lower than 79.55%(71/88)in adjacent tissues(χ^(2)=75.336,P<0.001).There was a significant negative correlation between PRMT5 and CDKN2B in cervical cancer(r=-0.734,P<0.001).The positive rates of PRMT5 and CDKN2B in cervical cancer tissues with different FIGO stages and lymph node metastasis were statistically significant(P<0.05).The cumulative 3-year progression free survival rates of the PRMT5 positive and negative groups were 74.19%(46/62)and 92.31%(24/26),respectively,the cumulative 3-year progression free survival rate of the PRMT5 positive group was lower than that of the PRMT5 negative group(Log Rankχ^(2)=4.386,P=0.017).The 3-year progression free survival rates of the CDKN2B negative and positive groups were 75.00%(51/68)and 95.00%(19/20),respectively,the cumula

关 键 词：宫颈癌 蛋白精氨酸甲基转移酶5 细胞周期蛋白依赖性激酶抑制剂2B 预后 肿瘤标志物 

分 类 号：R737.33[医药卫生—肿瘤]